Opexa's share price tumbles as lead MS drug fails
This article was originally published in Scrip
Shares in the US biotech company Opexa Therapeutics lost 94% of their value after a Phase IIb study of its lead product Tovaxin failed. The firm's share price on Nasdaq closed at $0.22 on September 19th after the top-line data were released at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada.
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.